Clinical trial NCT02291913: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Official title: Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: ER-Positive Breast Cancer
HER2-Negative Breast Cancer
everolimus
anti-estrogen therapy
PR-Positive Breast Cancer
Afinitor
Lead sponsor: SCRI Development Innovations, LLC
Sponsor class: OTHER
Collaborators: name: Novartis
First posted: 2014-11-17
Enrollment: 48
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression. Everolimus, in combination with exemestane, has shown activity in endocrine-resistant disease. This study will evaluate the efficacy of Everolimus+ anti-estrogen therapy in patients with ER-positive metastatic breast cancer who have progressed after receiving anti-estrogen therapy.

Detailed description: This is a multi-centered, open-labeled, Phase II study on metastastic breast cancer (MBC). The patient population includes locally recurrent or MBC patients with cytologically or histologically confirmed hormone receptor-positive breast cancer who have demonstrated disease progression on prior anti-estrogen therapy or therapies. Investigators propose to evaluate the efficacy of Everolimus in patients with ER-positive (estrogen receptor-positive) metastatic breast cancer who have progressed on anti-estrogen therapy. Forty-six (46) patients are planned for enrollment in the trial.

Eligibility criteria: Inclusion Criteria:

1. Histologic diagnosis of unresectable, locally recurrent or MBC.
2. ER and/or PR-positive tumors with staining by immunohistochemistry (IHC) based on the most recent biopsy.
3. Only 1 previous chemotherapy regimen for MBC. Patients progressing while receiving adjuvant endocrine therapy or progressing \<12 months from completion of adjuvant endocrine therapy are eligible.
4. Progressed on anti-estrogen therapy (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy) defined as:

   * Recurrence while on, or within 12 months of end of anti-estrogen therapy for early stage breast cancer, or
   * Progression while on, or within one month of anti-estrogen therapy for locally advanced or metastatic breast cancer.

   Note: No washout for anti-estrogen therapy required. Anti-estrogen therapy does not have to be the last treatment prior to study entry.
5. Post-menopausal or pre/peri-menopausal women on tamoxifen. LHRH agonists may be used to render ovarian suppression with postmenopausal ranges of estradiol or FSH per institutional guidelines.
6. HER2-negative breast cancer, defined as follows:

   * Fluorescent In Situ Hybridization (FISH)-negative (FISH ratio \<2.0), or
   * IHC 0-1+, or
   * IHC 2-3+ AND FISH-negative (FISH ratio \<2.0).
7. Measureable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable bone lesions, lytic or mixed, in absence of measureable disease by RECIST criteria.
8. Adequate hematologic, hepatic and renal function.
9. International normalized ratio (INR) ≤1.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy).
10. Age ≥ 18 years.
11. ECOG Performance Status score of 0-2.
12. Life expectancy of ≥ 12 weeks.

Exclusion Criteria:

1. Previous therapy or known intolerance/hypersensitivity with any approved or investigational mTOR inhibitor (e.g., temsirolimus, everolimus, sirolimus).
2. Patients who are ≤21 days after their most recent chemotherapy and have not recovered from side effects.
3. Use of an investigational drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of everolimus. For investigational drugs for which 5 half-lives is ≤21 days, a minimum of 10 days between termination of the investigational drug and administration of everolimus is required.
4. Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days for metastatic disease prior to first dose of everolimus or has not recovered from side effects of such therapy.
5. Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if there is no evidence of central nervous system (CNS) disease progression, and at least 2 weeks have elapsed since treatment. Patients are not permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs) during the study and should not be receiving chronic corticosteroid therapy for CNS metastases.
6. Patients with known active hepatitis B (HBV) or hepatitis C (HCV) infection. Patients with risk factors for hepatitis must have HBV DNA and HCV RNA testing by PCR, and are ineligible if these tests are positive.
7. Patients receiving immunization with attenuated live vaccines within 1 week of study entry or during study period.

NOTE: There are additional inclusion/exclusion criteria. The study center will determine patient eligibility and respond to any questions.

Primary outcomes:
measure: Median Progression Free Survival (PFS)
timeFrame: up to 3 years
Secondary outcomes:
measure: Number of Patients With Adverse Events (AEs) as a Measure of Safety and Tolerability
timeFrame: Up to 20 months
measure: Number of Patients With an Objective Response (CR or PR) Also Called the Overall Response Rate (ORR).
timeFrame: every 8 weeks until discontinuation, up to 20 months
measure: Number of Participants With CR, PR, or 6 Months of SD Also Called Clinical Benefit Rate (CBR)
timeFrame: Up to 20 months
measure: Median Time From First Occurrence of CR or PR to Disease Progression or Death Also Called Duration of Response (DOR)
timeFrame: every 8 weeks until discontinuation, up to 20 months
measure: Median Overall Survival (OS)
timeFrame: up to 3 years from first treatment
Other outcomes:
Locations:
city: Fort Myers
country: United States
facility: Florida Cancer Specialists-South
state: Florida
city: Hollywood
country: United States
facility: Memorial Cancer Center
state: Florida
city: Pensacola
country: United States
facility: Woodlands Medical Specialists
state: Florida
city: West Palm Beach
country: United States
facility: Florida Cancer Specialists-East
state: Florida
city: Terre Haute
country: United States
facility: Hope Cancer Center
state: Indiana
city: Chattanooga
country: United States
facility: Tennessee Oncology
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Fort Worth
country: United States
facility: Center for Cancer and Blood Disorders
state: Texas
Study officials:
affiliation: SCRI Development Innovations, LLC
name: Denise A. Yardley, MD
role: STUDY_CHAIR
References: